ICU Medical, Inc. (NASDAQ:ICUI – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the nine brokerages that are presently covering the company, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation, four have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $192.80.
Several research firms have commented on ICUI. Piper Sandler upped their price objective on shares of ICU Medical from $163.00 to $195.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Wall Street Zen raised shares of ICU Medical from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 8th. Zacks Research lowered shares of ICU Medical from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 28th. Raymond James Financial reissued a “strong-buy” rating and issued a $200.00 price target on shares of ICU Medical in a report on Friday, August 7th. Finally, Sanford C. Bernstein downgraded shares of ICU Medical to a “market perform” rating in a research report on Monday, June 15th.
Check Out Our Latest Report on ICUI
ICU Medical Price Performance
ICU Medical (NASDAQ:ICUI – Get Free Report) last issued its earnings results on Thursday, August 6th. The medical instruments supplier reported $2.37 EPS for the quarter, topping the consensus estimate of $1.91 by $0.46. The company had revenue of $547.88 million during the quarter, compared to the consensus estimate of $533.44 million. ICU Medical had a return on equity of 7.91% and a net margin of 1.39%.The firm’s revenue for the quarter was up .5% compared to the same quarter last year. During the same period in the previous year, the company posted $2.10 EPS. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. On average, analysts anticipate that ICU Medical will post 7.19 earnings per share for the current year.
Insider Activity at ICU Medical
In related news, COO Christian Voigtlander sold 8,929 shares of the business’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $182.93, for a total value of $1,633,381.97. Following the completion of the sale, the chief operating officer directly owned 37,377 shares in the company, valued at $6,837,374.61. The trade was a 19.28% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Daniel Woolson sold 5,417 shares of the stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $181.33, for a total value of $982,264.61. Following the transaction, the vice president owned 17,062 shares in the company, valued at $3,093,852.46. The trade was a 24.10% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 21,830 shares of company stock valued at $3,905,003 in the last 90 days. Corporate insiders own 2.10% of the company’s stock.
Hedge Funds Weigh In On ICU Medical
A number of hedge funds have recently bought and sold shares of ICUI. California State Teachers Retirement System grew its position in shares of ICU Medical by 14,236.6% during the 2nd quarter. California State Teachers Retirement System now owns 3,944,273 shares of the medical instruments supplier’s stock worth $578,230,000 after purchasing an additional 3,916,761 shares in the last quarter. BlackRock Inc. bought a new stake in shares of ICU Medical in the second quarter valued at approximately $550,250,000. Jupiter Topco LLC acquired a new stake in ICU Medical during the second quarter worth approximately $407,786,000. Millennium Management LLC grew its position in ICU Medical by 173.4% during the third quarter. Millennium Management LLC now owns 1,089,017 shares of the medical instruments supplier’s stock worth $130,638,000 after buying an additional 690,694 shares in the last quarter. Finally, Norges Bank bought a new position in ICU Medical during the 4th quarter worth $58,083,000. 96.10% of the stock is owned by institutional investors.
ICU Medical Company Profile
ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.
Read More
- Five stocks we like better than ICU Medical
- Qualcomm’s Data Center Bet Looks More Real After Amazon’s AI Deal
- GE Aerospace’s $11.75B Deal Puts Howmet Aerospace in Focus
- Casey’s Post-Earnings Drop May Give Investors a Better Entry Into a Quality Retailer
- Sovereign AI: Palantir and Nebius Cut the Cloud Cord
Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.
